← Back to patent-cliff list
Sparsentan
Tier C — Watch / tradeSparsentan
Bristol Myers Squibb
Originator
2023
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：ETAR, AT1
Brand：Filspari
Indications (approved)：局灶性节段性肾小球硬化症, 免疫球蛋白a肾病
Regional status
US
Approved
2023-02-17
EU
Approved
2024-04-19
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Sparsentan?
Approved indications include: 局灶性节段性肾小球硬化症, 免疫球蛋白a肾病.
When does the Sparsentan patent expire?
No public expiry year is available for Sparsentan yet; this page updates once verified.
How do I get a quote for Sparsentan intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27